The Prime 5 Psychedelic Firms to Watch in 2022


The yr 2021 has not been sort to the psychedelics business. The inventory performances of the 60 publicly traded psychedelics corporations on the Psychedelic Inventory Index have been trending steadily downward since February 22, 2021, to their lowest level because the index started on June 1, 2020.

The pandemic has positively affected psychedelic enterprise improvement. Nonetheless, just a few corporations are getting nearer to providing merchandise and increasing remedy companies. So a looming good storm of extra psychedelic corporations laying the groundwork for additional improvement could encourage a enterprise rebound in 2022.

Listed here are our picks for the 5 psychedelic corporations to observe in 2022:

Atai Life Sciences, Berlin, Germany – listed on NASDAQ (ATAI) since July, 2021 – Market cap $999 million

Atai Life Sciences, a clinical-stage biopharmaceutical firm aiming to rework the therapy of psychological well being issues, can be one of many largest shareholders in Compass Pathways. In December, 2021, Atai Affect, launched in October, 2021 because the philanthropic program of Atai Life Sciences, introduced its first main initiative, the institution of the Atai $2 million Fellowship Fund in Psychedelic Neuroscience in collaboration with Massachusetts Basic Hospital’s Middle for the Neuroscience of Psychedelics. The corporate additionally entered right into a sequence of joint ventures and acquisitions in 2021, together with with Psyber, a globally primarily based startup centered on the event of brain-computer interface-enabled digital therapeutics for treating psychological well being points. What’s coming in 2022: In January, 2022, the U.S. Meals and Drug Administration (FDA) gave Atai Investigational New Drug (IND) clearance to conduct a scientific examine of ketamine. Atai plans to provoke the examine early this yr by way of its platform firm Notion Neuroscience.

Compass Pathways, London, England – listed on NASDAQ (CMPS) since September 2020 – Market cap $751 million

READ ALSO  GRN Holdings To Grow to be Marijuana Inc. in Main Restructure

Compass Pathways is a psychological well being care firm devoted to accelerating affected person entry to evidence-based innovation in psychological well being. Compass has accomplished a section IIb scientific trial of psilocybin remedy for therapy resistant despair in 22 websites throughout Europe and North America, one of many largest randomized, managed, double-blind psilocybin remedy scientific trial ever performed. Compass can be working a section II scientific trial of COMP360 psilocybin remedy for post-traumatic stress dysfunction (PTSD).  What’s coming in 2022: The corporate is getting ready for a gathering with the FDA in early 2022 to finalize a program utilizing their psilocybin remedy, and anticipates commencing that program late in 2022.

Cybin, Toronto, Ontario, CNlisted on NYSE (CYBN) since August 2021 – Market cap $192 million

Cybin is a number one biotechnology firm centered on progressing psychedelic therapeutics by using proprietary drug discovery platforms, revolutionary drug supply methods, novel formulation approaches and therapy regimens for psychiatric issues. It was the primary psychedelics firm to commerce on the NYSE in August, 2021. The corporate has raised simply over $96 million up to now to fund scientific trials, M&A and IP methods. What’s coming in 2022: In October 26, 2021, the FDA approved an IND utility to proceed with the corporate’s sponsored feasibility examine utilizing Kernel’s Move know-how to measure ketamine’s psychedelic impact on cerebral cortex hemodynamics (mind movement blood). Kernel Move makes use of pulsed gentle as an alternative of steady wave gentle to extend measured mind data. Kernel Move is a wearable machine the dimensions and look of a bicycle helmet. Sooner or later, it might be extra broadly used for neuroscientific or physiological research of mind exercise throughout psychedelic use.

Subject Journey Well being, Toronto, CN – listed on NASDAQ (FTRP) since July 2021 – Market cap $149 million

READ ALSO  New York Choose Points Exemptions to Hashish Retail Injunction, Permits Two Shops to Open

Subject Journey does analysis and improvement on novel, psychedelic-inspired regulated medicines, and operates clinics that ship ketamine-assisted psychotherapy in Canada and the US. Subject Journey presently operates and/or owns 9 clinics in Toronto, Ontario; Fredericton, 

New Brunswick; New York, New York; Santa Monica, California; Chicago, Illinois; Atlanta, Georgia; Seattle, Washington; Houston, Texas; and Amsterdam, The Netherlands. What’s coming in 2022: The corporate is planning to construct an extra 9 Subject Journey Well being Facilities in Vancouver, British Columbia; San Diego, California; Washington, DC; Stamford, Connecticut; San Carlos, California; Austin, Texas; Scottsdale, Arizona; Dallas, Texas; and Miami, Florida. On January, 2022, Subject Journey introduced that the U.S. Patent and Trademark Workplace (USPTO) issued a Discover of Allowance for Subject Journey’s patent utility for his or her first novel psychedelic molecule in improvement. Subject Journey expects the patent to be issued in February, 2022.

MindMed, New York, NY – listed on NASDAQ (MNMD) since April 2021. Market cap $357 million.

MindMed is a clinical-stage biotech firm that seeks to find, develop and deploy psychedelic-inspired medicines and therapies to deal with psychological well being and habit. What’s coming in 2022: On January 4, 2022, the corporate introduced the completion of its Part 1 scientific trial of 18-MC, the corporate’s non-hallucinogenic proprietary by-product of ibogaine, being developed for the therapy of indications linked to opioid use dysfunction. This section 1 single and a number of ascending dose trial performed at a single scientific analysis web site in Perth, Australia, evaluated the protection, tolerability, pharmacokinetics, and results on the cognitive exercise of 18-MC in wholesome volunteers. The trial was accomplished in December 2021 with outcomes anticipated in early 2022.

Sources: Firm SEC filings; Yahoo! Finance; Psychedelic Inventory Index; firm web sites and press releases

Put up Views:



The statements made regarding these merchandise haven’t been evaluated by the Meals and Drug Administration. The efficacy of these merchandise has not been confirmed by FDA-approved evaluation. These merchandises are often not meant to diagnose, cope with, treatment, or forestall any sickness. All knowledge discovered proper right here won’t be meant as another option to or totally different from knowledge from well-being care practitioners. Please search the recommendation of your well-being care expert about potential interactions or totally different attainable points sooner than using any product. The Federal Meals, Drug and Magnificence Act requires this discovery.

READ ALSO  Pending Patents: Can Any Firm Personal Psilocybin?